Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD7 specific CAR T cell therapy - Hebei Taihe Chunyu Biotechnology

Next Previous
Drug Profile

CD7 specific CAR T cell therapy - Hebei Taihe Chunyu Biotechnology

Latest Information Update: 20 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebei Taihe Chunyu Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II T-cell lymphoma
  • Phase I/II Haematological malignancies

Most Recent Events

  • 12 Aug 2025 Hebei Taihe Chunyu Biotechnology in collaboration with Zhengzhou University plans a phase I/II trial for T-cell-lymphoma (Second-line or greater therapy) in China (IV, Infusion)in September 2025 (NCT07117305)
  • 01 Jun 2025 Phase-II clinical trials in T-cell lymphoma (Combination therapy, Late-stage disease) in China (IV) (NCT07106723)
  • 01 Jun 2025 Hebei Taihe Chunyu Biotechnology plans a clinical trial for T cell lymphoma/ Acute leukemia (Second-line therapy or greater, In adolescents, In adults, In the elderly) in June 2025 (IV, Infusion) (NCT07008872)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top